Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
NEW HAVEN, Conn., May 02, 2017 -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 42nd Annual Health Care Conference on Thursday, May 4, 2017, at 10:00 a.m. ET at the Intercontinental Boston Hotel in Boston, MA.
The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to pursue best-in-class oral antiviral therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement factor D inhibitors for AP-mediated diseases. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com.
Investors & Media: Glenn Schulman Achillion Pharmaceuticals, Inc. Tel. (203) 752-5510 [email protected]
